<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="178">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00003308</nctid>
  <trial_identification>
    <studytitle>Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma</studytitle>
    <scientifictitle>A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E-6397</secondaryid>
    <secondaryid>CDR0000066255</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Cancer</healthcondition>
    <healthcondition>Melanoma (Skin)</healthcondition>
    <healthcondition>Metastatic Cancer</healthcondition>
    <healthcondition>Ovarian Cancer</healthcondition>
    <healthcondition>Sarcoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bone</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - stereotactic radiosurgery

Treatment: other: stereotactic radiosurgery


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed renal cell carcinoma, melanoma, or sarcoma with 1-3 newly
             diagnosed intraparenchymal brain metastases based on contrast-enhanced MRI (CT scan
             acceptable if patients have a medical contraindication to MRI)

          -  No lesion greater than 4.0 cm in diameter and, if multiple lesions are present, no
             more than one greater than 3.0 cm in diameter

          -  No limitation on the extent of extracranial metastatic disease

          -  No metastases in the brain stem, midbrain, pons, or medulla

          -  No leptomeningeal metastases documented by MRI or CSF evaluation

          -  No metastases within 10 mm of optic nerve or chiasm

          -  No history of multiple liver metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 50,000/mm^3

          -  Hemoglobin greater than 8 g/dL

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No major medical illness

          -  No psychoses

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior chemotherapy allowed

          -  Systemic chemotherapy may be continued at the discretion of investigator after
             completion of radiosurgery

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior cranial radiotherapy

          -  Prior or concurrent radiotherapy to noncranial sites allowed

        Surgery:

          -  No prior surgical resection for brain metastases

          -  Prior stereotactic biopsy for diagnostic purposes allowed</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Westmead Hospital - Westmead</hospital>
    <postcode>2145 - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Eastern Cooperative Oncology Group</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients
      with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00003308</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Minesh P. Mehta, MD</name>
      <address>University of Wisconsin, Madison</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>